Comparative Study of Intravitreal Injection of Conbercept and Ranibizumab Combined with Trabeculectomy in the Treatment of Neovascular Glaucoma
Objective:To compare the effect of trabeculectomy with conbercept and ranibizumab in the treatment of neovascular glaucoma (NVG). Methods:A total of 110 patients with NVG admitted to Zhengzhou Overke Eye Hospital from June 2019 to May 2022 were randomly divided into control group and observation group,with 55 patients in each group. All patients received routine intervention and trabeculectomy. The control group was treated with ranibizumab,and the observation group was treated with conbercept. The clinical efficacy,visual acuity,intraocular pressure,neovascularization area,neovascularization regression time and complications were compared between the two groups. Results:There was no significant difference in the total effective rate,visual acuity,intraocular pressure and complication rate between the two groups (P>0.05). On the 7 th day of treatment,the area of neovascularization in the two groups was smaller than that before treatment,and the observation group was smaller than the control group (P<0.05). The regression time of neovascularization in the observation group was shorter than that in the control group (P<0.05). Conclusion:The effects of intravitreal injection of conbercept and ranibizumab combined with trabeculectomy in the treatment of NVG are equivalent,which can effectively improve the intraocular pressure and visual acuity of the affected eyes. However,compared with ranibizumab,conbercept is more conducive to improving the regression effect of neovascularization.
万方数据
维普
